Cargando…
The New Era of Immunotherapy in Gastric Cancer
SIMPLE SUMMARY: Advanced gastric cancer remains a malignancy with a poor prognosis, with a median survival of about 12–15 months. In recent years, immune checkpoint inhibitors have emerged as a new standard of care for several malignancies, including advanced gastric cancer, and have demonstrated go...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870470/ https://www.ncbi.nlm.nih.gov/pubmed/35205802 http://dx.doi.org/10.3390/cancers14041054 |